Lenalidomide added to bendamustine-rituximab for untreated chronic lymphocytic leukemia (CLL): A phase 1 study.

被引：0
|
作者：
Abramson, Jeremy S.
Davids, Matthew Steven
Werner, Lillian
Fisher, David Christopher
Armand, Philippe
Amrein, Philip C.
Neuberg, Donna S.
Hochberg, Ephraim P.
Brown, Jennifer R.
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7082
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study (vol 97, pg 1, 2018)
    Egle, Alexander
    Steurer, Michael
    Melchardt, Thomas
    Weiss, Lukas
    Gassner, Franz Josef
    Zaborsky, Nadja
    Geisberger, Roland
    Catakovic, Kemal
    Hartmann, Tanja Nicole
    Pleyer, Lisa
    Voskova, Daniela
    Thaler, Josef
    Lang, Alois
    Girschikofsky, Michael
    Petzer, Andreas
    Greil, Richard
    ANNALS OF HEMATOLOGY, 2018, 97 (09) : 1745 - 1745
  • [32] Phase II multicenter trial of pentostatin and rituximab in patients with previously treated and untreated chronic lymphocytic leukemia (CLL).
    Yunus, F
    George, S
    Smith, J
    Geils, G
    Geils, G
    BLOOD, 2003, 102 (11) : 360B - 361B
  • [33] Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Kipps, Thomas J.
    Wierda, William G.
    Jones, Jeffrey A.
    Swinnen, Lode J.
    Yang, Jianning
    Cui, Yue
    Busman, Todd
    Krivoshik, Andrew
    Enschede, Sari
    Humerickhouse, Rod
    BLOOD, 2010, 116 (21) : 1019 - 1019
  • [34] Cost-Effectiveness of Zanubrutinib Versus Bendamustine and Rituximab in Patients With Untreated Chronic Lymphocytic Leukemia
    Nie, Jing
    Liu, Lihui
    Wu, Huina
    Yuan, Shan
    Tang, Ke
    Wu, Jiyong
    CLINICAL THERAPEUTICS, 2024, 46 (11) : 877 - 882
  • [35] NAVITOCLAX (ABT-263) PLUS FLUDARABINE/CYCLOPHOSPHAMIDE/RITUXIMAB (FCR) OR BENDAMUSTINE/RITUXIMAB (BR): A PHASE 1 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Kipps, T.
    Swinnen, L.
    Wierda, W.
    Jones, J.
    Coutre, S.
    Smith, M.
    Yang, J.
    Cui, Y.
    Chyla, B.
    Busman, T.
    Enschede, S.
    Humerickhouse, R.
    HAEMATOLOGICA, 2012, 97 : 219 - 219
  • [36] Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Kipps, Thomas J.
    Swinnen, Lode J.
    Wierda, William G.
    Jones, Jeffrey Alan
    Coutre, Steven E.
    Smith, Mitchell R.
    Yang, Jainning
    Cui, Yue
    Busman, Todd
    Enschede, Sari
    Humerickhouse, Rod
    BLOOD, 2011, 118 (21) : 1669 - 1669
  • [37] Sequoia: Results of a randomized phase iii trial of zanubrutinib versus bendamustine plus rituximab (br) in patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
    Greil, R.
    Robak, T.
    Giannopoulos, K.
    Jurczak, W.
    Simkovic, M.
    Shadman, M.
    Oesterborg, A.
    Laurenti, L.
    Walker, P.
    Opat, S.
    Chan, H.
    Ciepluch, H.
    Tani, M.
    Trneny, M.
    Brander, D. M.
    Flinn, I. W.
    Grosicki, S.
    Verner, E.
    Brown, J. R.
    Kahl, B. S.
    Ghia, P.
    Li, J.
    Tian, T.
    Zhou, L.
    Marimpietri, C.
    Paik, J. C.
    Cohen, A.
    Hillmen, P.
    Tam, C. S.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 117 - 118
  • [38] Phase 1 Trial of Flavopiridol and Lenalidomide In Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL)
    Blum, Kristie A.
    Jones, Jeffrey A.
    Andritsos, Leslie
    Flynn, Joseph M.
    Deam, Deidre
    Heerema, Nyla A.
    Phelps, Mitchell
    Johnson, Amy J.
    Grever, Michael R.
    Byrd, John C.
    BLOOD, 2010, 116 (21) : 1027 - 1027
  • [39] A phase II study of the combination of lenalidomide and rituximab as frontline treatment in patients with chronic lymphocytic leukemia
    Strati, Paolo
    Thompson, Philip
    Keating, Michael
    Hinojosa, Christina
    Rodriguez, Diana
    Jain, Nitin
    Burger, Jan A.
    Estrov, Zeev
    O'Brien, Susan
    Wierda, William
    Ferrajoli, Alessandra
    LEUKEMIA & LYMPHOMA, 2017, 58 : 70 - 72
  • [40] BRUIN CLL-313: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)
    Jurczak, Wojciech
    Dartigeas, Caroline
    Coscia, Marta
    Ganly, Peter S.
    Al-Jazayrly, Ghassan
    Wang, Chunxiao
    Bao, Katherine
    Leow, Ching Ching
    Shahda, Safi
    Zinzani, Pier Luigi
    BLOOD, 2021, 138 : 3732 - +
12345